ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary ...
Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2026" has been added to ResearchAndMarkets.com's offering.The Co-development Deals in ...
Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026" has been added to ResearchAndMarkets.com's offering.Fully ...
Hosted on MSN
Transformative trends in life sciences: The future of pharmaceuticals and biotechnology
The life sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices, is experiencing unprecedented advancements driven by scientific innovation. Technologies such as artificial ...
The company has tremendous prospects.
X4 Pharmaceuticals is rated BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. XFOR's primary value lies in its 4WARD Phase 3 trial in ...
December 2025 marked an exceptionally active period for life sciences regulation in the European Union (EU). Within the space of a few days, EU institutions have reached political agreement on the ...
ARC Advisory Group today announced the publication of its new ARC MarketMap for Manufacturing Execution Systems (MES) in Pharmaceutical & Biotech Industries, an independent research study evaluating ...
DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public ...
Vertex Pharmaceuticals is best known for developing medicines that treat cystic fibrosis (CF), an area where it has no meaningful competition. Some investors worry that this might change soon, as ...
ADARx sets IPO goal: ADARx Pharmaceuticals aims for a Nasdaq listing valued at up to $1.74 billion, signaling strong investor interest. Biotech index outperforms: The XBI index has risen 25% in 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results